Evidence map›Paper›PMID 33428584›Full record

ReviewJournal for immunotherapy of cancer2020

Landscape of natural killer cell activity in head and neck squamous cell carcinoma.

Andrew J Charap, Tomohiro Enokida, Rachel Brody, John Sfakianos, Brett Miles, Nina Bhardwaj, Amir Horowitz

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Role ofTranslational cancer research · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. The Role ofCancers · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Differential impact of TIM-3 ligands on NK cell function.Journal for immunotherapy of cancer · 2025
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Andrew J CharapOncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Tomohiro EnokidaMedicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Rachel BrodyPathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
John SfakianosUrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Brett MilesOtolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Nina BhardwajMedicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Amir HorowitzOncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA amir.horowitz@mssm.edu.
Icahn School of Medicine at Mount Sinai · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) encompasses a set of cancers arising from the epithelia of the upper aerodigestive tract, accounting for a significant burden of disease worldwide due to the disease's mortality, morbidity, and predilection for recurrence. Prognosis of HNSCC in the recurrent and/or metastatic (R/M-HNSCC) setting is especially poor and effective treatment options increasingly rely on modulating T-cell antitumor responses. Still, immunotherapy response rates are generally low, prompting the exploration of novel strategies that incorporate other effector cells within the tumor microenvironment. Within the last decade, important advances have been made leveraging the powerful innate antitumor function of natural killer (NK) cells to treat solid tumors, including head and neck squamous cell carcinoma. NK cells are hybrid innate-adaptive effector cells capable of directly eliminating tumor cells in addition to initiating adaptive antitumor immune responses. In the setting of HNSCC, NK cells are important for tumor surveillance and control, and NK cell infiltration has repeatedly been associated with a favorable prognosis. Yet, HNSCC-infiltrating NK cells are susceptible to an array of immune evasion strategies employed by tumors that must be overcome to fully realize the antitumor potential of NK cells. We believe that a conceptual framework informed by the basic biological understanding of the mechanisms underlying NK cell activation can improve treatment of HNSCC, in part by selecting for patients most likely to respond to NK cell-based immunotherapy. Herein, we review the activity of NK cells in HNSCC, paying special attention to the role of environmental and genetic determinants of NK cell antitumor function. Moreover, we explore the evidence that NK cells are a crucial determinant of the efficacy of both established and emerging treatments for HNSCC.

Indexed as

Cell Line, TumorHumansKiller Cells, NaturalSquamous Cell Carcinoma of Head and NeckTumor Microenvironmentantigen presentationcostimulatory and inhibitory T-cell receptorscytotoxicityhead and neck neoplasmsimmunologickiller cellsnatural

Identifiers

PMID33428584
PMCPMC7754625
OpenAlexW3114678387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.